2-amino-3-methyl-6-((1S,2R)-2-(3-(phenylethynyl)phenyl)cyclopropyl)pyrimidin-4(3H)-one | 1431792-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-amino-3-methyl-6-((1S,2R)-2-(3-(phenylethynyl)phenyl)cyclopropyl)pyrimidin-4(3H)-one
• 英文别名: 2-amino-3-methyl-6-[(1S,2R)-2-[3-(2-phenylethynyl)phenyl]cyclopropyl]pyrimidin-4-one
• CAS: 1431792-74-3
• 化学式: C₂₂H₁₉N₃O
• 分子量: 341.412
• InChiKey: XZBJZXIRQFLKGS-OALUTQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 以17%的产率得到2-amino-3-methyl-6-((1S,2R)-2-(3-(phenylethynyl)phenyl)cyclopropyl)pyrimidin-4(3H)-one
  参考文献：
  名称：

  Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring

  摘要：

  To improve the efficacy of the conformationally restricted BACE1 inhibitors, structural modifications were investigated using two strategies: (a) modification of the terminal aromatic ring and (b) insertion of a spacer between the aromatic rings. In the latter approach, another type of inhibitor 17 bearing an ethylene spacer between two aromatic rings was found to exhibit good BACE1 inhibitory activity, while the corresponding conformationally unrestricted compound 25 showed no activity. This result revealed an interesting effect of a conformational restriction with a cyclopropane ring. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.056

文献信息

• [EN] CYCLOPROPANE DERIVATIVE HAVING BACE1 INHIBITING ACTIVITY<br/>[FR] DÉRIVÉ DE CYCLOPROPANE PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE BACE1
  申请人：SHIONOGI & CO

  公开号：WO2014010748A1

  公开（公告）日：2014-01-16

  The present invention relates to compounds of the Formula (I) and (II): wherein each variable is as defined in the specification, pharmaceutically acceptable salts and solvates thereof, as well as use of such compounds as a BACE1 inhibitor. The compounds of the invention are useful as an agent for treating a disease induced by production, secretion and/or deposition of amyloid β protein.

  本发明涉及化合物的结构式(I)和(II)：其中每个变量如规范中所定义，其药用盐和溶剂合物，以及将这些化合物用作BACE1抑制剂。本发明的化合物可用作治疗由淀粉样蛋白β的产生、分泌和/或沉积引起的疾病的药物。
• Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring
  作者：Shuji Yonezawa、Hidekuni Yamakawa、Chie Muto、Motoko Hosono、Takahiko Yamamoto、Kazunari Hattori、Masahiro Sakagami、Hiroko Togame、Yoshikazu Tanaka、Toru Nakano、Hiroshi Takemoto、Mitsuhiro Arisawa、Satoshi Shuto

  DOI：10.1016/j.bmcl.2013.03.056

  日期：2013.5

  To improve the efficacy of the conformationally restricted BACE1 inhibitors, structural modifications were investigated using two strategies: (a) modification of the terminal aromatic ring and (b) insertion of a spacer between the aromatic rings. In the latter approach, another type of inhibitor 17 bearing an ethylene spacer between two aromatic rings was found to exhibit good BACE1 inhibitory activity, while the corresponding conformationally unrestricted compound 25 showed no activity. This result revealed an interesting effect of a conformational restriction with a cyclopropane ring. (C) 2013 Elsevier Ltd. All rights reserved.